ASCO 2020：11项华北地区研究入选口头报告，17项Poster报告

受亚洲地区新冠鼠疫受到影响，原定于5月29日~6月2日在芝加哥举行的英国流行病学学会（ASCO）年会今年将首次以线上方式举办，这是目前最大规模的线上大型活动。今天，代表大会的摘录短文公布，共103个sessions，里面国共有11项研究课题入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

酮类替尼或拉帕替尼加卡培他鹿岛用以HER2+冠心病乳腺胰脏（PHOEBE）：一项III期随机飞行测试。

专场：冠心病乳腺胰脏

所作：里面国医学科学院该医院徐兵河博士、马飞博士，北京师范大学附属该医院胡夕春博士等

摘录号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态乳腺胰脏标准放射治疗后卡培他鹿岛保持稳定节拍肌肉注射的III期飞行测试（SYSUCC-001）。

专场：乳腺胰脏—发散/区域/主要用途放射治疗

所作：里面山大学预防外围君树森博士等

摘录号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

来进行冠心病脑细胞会的表型特征来预测脑细胞会脊液里面循环DNA检测的概率: 新机器对抗老对手

专场：新机器解决问题老问题

所作：李美芹 李阿马等

摘录号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对福林拉非尼作为后半期肝细胞会胰脏的一线放射治疗：一项全站页面、随机、多外围II/III期飞行测试。

专场：腹腔肠道胰脏—腹腔膀胱、肾上腺和实无

所作：南京大学特罗斯季亚涅齐该医院毕锋博士、里面国团结解放军南开该医院秦叔逵博士等

摘录号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里面国后半期肝胰脏病征阿帕替尼主干线放射治疗：一项随机、安慰剂比对、结果显示III期研究课题

专场：腹腔肠道胰脏—腹腔膀胱、肾上腺和实无

所作：里面国团结解放军南开该医院秦叔逵博士、南京大学特罗斯季亚涅齐该医院李秋博士等

摘录号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期罹患病态卵巢胰脏二次细胞会减灭术的一项随机III期飞行测试：SOC1 / SGOG-OV2。

专刊：妇科胰脏症

所作：北京师范大学附属里面山该医院臧荣余博士等

摘录：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治病态子宫切除术后主要用途放射治疗里面的序贯放肌肉注射对比实际上皮肤癌或同步放肌肉注射（STARS研究课题）：一项随机、比对、全站页面的III期飞行测试。

代表大会：妇科胰脏症

所作：里面山大学预防外围苍博士、刘继红博士等

摘录号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比肌肉注射用以可切除的EGFR凋亡的N1-N2期NSCLC-随机III期乳腺胰脏的最终相比之下求生比对。

专刊：肺胰脏—非小细胞会发散-区域/小细胞会/其他胸部

所作：广东省团结该医院吴一龙博士等

摘录号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡；不分散非小细胞会肺胰脏病征一线代谢物丝氨酸肽倡议或不倡议不遗余力机动部队发散皮肤癌：III期全站页面流行病学随机飞行测试（SINDAS）的里面期结果（NCT02893332）。

专刊：肺胰脏-非小细胞会分散

所作：南充团结该医院曾铭博士等

摘录：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类幸存者-1（PD-1）的人源化IgG4单克隆抗体倡议阿昔替尼用以冠心病黏膜前列腺癌病征的Ib期研究课题的总求生期和微生物研究课题比对。

专刊：前列腺癌/皮肤胰脏

所作：北京大学该医院郭军、盛锡楠博士等

摘录：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用病态和结果：通用CAR-T细胞会首次化学物质飞行测试放射治疗罹患/难治病态T细胞会急病态细胞会会肺炎（r/r T-ALL）的实用病态和。代表大会：开发设计里面的放射治疗技术-免疫放射治疗。所作：君欣欣等摘录：3013月历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期膀胱鳞状细胞会胰脏病征里面的系统设计：一项随机的全站页面II期飞行测试（ORIENT-2）。代表大会：腹腔肠道胰脏-腹腔膀胱胰脏、肾上腺胰脏和实无道胰脏所作：徐建明博士等摘录：4511月历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T细胞会对髓母细胞会瘤的根治病态放射治疗代表大会：里面枢神经系统所作：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东摘录：2522月历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病征里面的系统设计代表大会：开发设计里面的放射治疗学-免疫放射治疗所作：沈琳博士等摘录：3021月历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗罹患/难治病态ACUTE细胞会会肺炎/淋巴瘤的首例化学物质乳腺胰脏代表大会: 开发设计病态放射治疗学-免疫放射治疗所作简介：张明志，杨林等摘录：3026月历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议系统设计以后半期本体瘤病征的Ib期研究课题代表大会：发展病态放射治疗学---小分子靶向药品和微生物学所作：龚继芳，沈琳博士等摘录：3523月历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议紫杉醇和nedaplatin放射治疗罹患病态或冠心病膀胱鳞状细胞会胰脏（ESCC）病征的II期研究课题。代表大会：腹腔肠道胰脏-腹腔膀胱、肾上腺和实无道胰脏的研究课题所作：君志极强，李玉红，君德申，君凤华，任超，谭琼 君志极强、李玉红、君德深、君凤华、任超、谭琼摘录：4522月历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大会：腹腔肠道胰脏-腹腔膀胱胰脏、肾上腺胰脏和实无管胰脏的主干线放射治疗所作：宋艳等摘录：4524月历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体的环RNA分类器用以初始恶性肿瘤时检测高等级胰脏的尿液外体的环RNA分类器：一项多外围的回顾病态研究课题代表大会：泌尿循环系统胰脏症那是胰脏、睾丸胰脏和胰脏所作简介：Liaoyuan Li等摘录：5522月历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散后半期宫颈胰脏即刻肌肉注射后的主要用途肌肉注射代表大会: 妇科胰脏症所作简介： 李珉珉等摘录：6031月历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗甲状腺髓病态胰脏的相关病态：基于ALTER01031飞行测试的比对。会话：头颈部所作：天津市该医院娴熟博士摘录：6526月历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼放射治疗后病征剧情的受到影响: ALTER01031的亚组比对代表大会：头颈部所作：天津市该医院娴熟博士摘录：6527月历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预测I-IIIA期非小细胞会肺胰脏（NSCLC）病征术后罹患: GASTO1035和GASTO1018的结果代表大会：肺胰脏-非小细胞会发散-区域病态/小细胞会/小细胞会/其他胸科胰脏症所作：Si-Yu Wang等摘录：9023月历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会肺胰脏（NSCLC）里面EGFR代谢物丝氨酸肽的新型抗药病态机制代表大会:肺胰脏-非小细胞会冠心病肺胰脏所作简介：赵昕，金结缘，满宇，欧真假，和黄，薛武，杨少，范敏 赵昕、金结缘、满宇、欧真假、和黄、薛武、杨绍、范敏摘录：9528月历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1飞行测试里面后半期前列腺癌总求生的替代终点代表大会：前列腺癌/皮肤胰脏所作：聂润聪，袁书极强，李元芳，陈英波，周志伟 聂润聪、袁书极强、李元芳、陈英波、周志伟摘录：10030月历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗罹患或冠心病原发病态恶病态穿孔病征的II期研究课题代表大会： 性疾病所作：唐丽娜，牛晓辉，君震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、君振、蔡启庆、涂崇奇、范正福、杨瑶摘录：11525月历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞扬安罗替尼在后半期性疾病病征多线放射治疗里面的实用病态和。代表大会：性疾病所作：姚伟涛，君家极强，张瑞，君欣，杜新辉，田志浩，牛晓颖 姚伟涛、君家极强、张瑞、君鑫、杜鑫辉、田志超、牛晓英摘录：11526月历：414